Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19208663 | ANTIHYPERTENSIVE PEPTIDE PROBIOTIC GOAT MILK POWDER AND PREPARATION METHOD THEREOF | May 2025 | December 2025 | Allow | 7 | 2 | 1 | No | No |
| 18526264 | Novel Strain of Glutamicibacter, Originating from Insects, Capable of Efficiently Degrading Bifenthrin | December 2023 | June 2024 | Allow | 7 | 2 | 1 | No | No |
| 18502098 | PROBIOTIC COMPOSITIONS AND USES THEREOF | November 2023 | December 2024 | Allow | 13 | 1 | 0 | Yes | No |
| 18500327 | AGENT FOR IMPROVING MITOCHONDRIAL FUNCTION | November 2023 | July 2025 | Abandon | 20 | 2 | 0 | No | No |
| 18287028 | LACTOBACILLUS REUTERI AND USE, COMPOSITION, DRUG AND FOOD THEREOF | October 2023 | November 2025 | Allow | 25 | 2 | 0 | No | No |
| 18140191 | PRODUCTS AND METHODS FOR EXTENDING THE SHELF LIFE OF WATER SENSITIVE PRODUCTS | April 2023 | October 2025 | Abandon | 29 | 5 | 0 | No | Yes |
| 18041191 | LACTIC ACID BACTERIA COMPOSITION STABLE UNDER STRONG ACIDIC CONDITIONS | February 2023 | January 2026 | Abandon | 35 | 1 | 0 | No | No |
| 18158543 | Cardiovascular Health-Promoting Composition | January 2023 | August 2025 | Abandon | 31 | 4 | 1 | No | No |
| 18003169 | SYNBIOTIC COMPOSITION | December 2022 | December 2025 | Abandon | 36 | 0 | 1 | No | No |
| 18086954 | METHOD OF DEVELOPMENT OF SELECTIVE PROBIOTIC GROWTH PROMOTORS AND SELECTIVE PATHOGEN GROWTH INHIBITORS FROM KIMCHI FERMENTATION | December 2022 | January 2026 | Abandon | 37 | 3 | 1 | No | No |
| 17982611 | METHOD FOR PREPARING AGROCYBE CYLINDRACEA FERMENTED KUDZUVINE ROOT AND COIX SEEDS BEVERAGE | November 2022 | February 2024 | Abandon | 15 | 1 | 1 | No | No |
| 17982956 | EDTA System for Reducing Browning in Mycohide Materials | November 2022 | November 2023 | Abandon | 12 | 1 | 0 | No | No |
| 17922041 | NOVEL LACTIC ACID BACTERIA HAVING EXCELLENT IMMUNE FUNCTION ENHANCEMENT EFFECT, AND FOOD COMPOSITION, HEALTH FUNCTIONAL FOOD COMPOSITION AND PROBIOTICS COMPRISING SAME | October 2022 | November 2025 | Abandon | 37 | 1 | 0 | No | No |
| 18047658 | METHOD OF USING LACTOBACILLUS FERMENTUM TCI757 FOR GAINING MUSCLE, PROMOTING SECRETION OF IRISIN, AND DECREASING VISCERAL FAT | October 2022 | January 2025 | Allow | 27 | 3 | 0 | Yes | No |
| 17958303 | PRODUCTS AND METHODS FOR EXTENDING THE SHELF LIFE OF WATER SENSITIVE PRODUCTS | September 2022 | October 2025 | Abandon | 37 | 5 | 1 | Yes | No |
| 17955287 | METHOD AGAINST SALMONELLA TYPHIMURIUM INFECTION WITH SYMBIOTIC COMPOSITION | September 2022 | September 2023 | Allow | 12 | 2 | 0 | Yes | No |
| 17887025 | FERMENTATE WITH ANTI-INFLAMMATORY AND IMMUNE MODULATING PROPERTIES | August 2022 | March 2025 | Allow | 31 | 2 | 1 | Yes | No |
| 17818591 | PROBIOTIC COMPOSITION TO REDUCE PATHOGENESIS IN POULTRY AND METHODS FOR USE THEREOF | August 2022 | February 2025 | Abandon | 30 | 3 | 1 | No | No |
| 17818182 | PROBIOTIC EGG WASH | August 2022 | February 2026 | Abandon | 43 | 2 | 0 | No | No |
| 17817710 | Protection of Next-Generation Probiotics during Processing | August 2022 | October 2023 | Abandon | 15 | 1 | 1 | No | No |
| 17760112 | NOVEL STRAIN OF LACTOBACILLUS SAKEI HEM224, AND COMPOSITION FOR TREATING INFLAMMATION OR ASTHMA COMPRISING STRAIN OR CULTURED PRODUCT THEREOF | August 2022 | August 2025 | Allow | 36 | 2 | 0 | Yes | No |
| 17796439 | COMPOSITIONS AND METHODS FOR TREATING BIOFILMS, INFECTIONS AND PERIODONTITIS | July 2022 | September 2025 | Abandon | 38 | 0 | 1 | No | No |
| 17872540 | METHOD FOR ANALYZING ILEOSTOMY SUBJECTS USING A PROBIOTIC CONTAINING BACILLUS SUBTILIS | July 2022 | November 2023 | Abandon | 16 | 3 | 1 | No | No |
| 17859837 | SYNECHOCOCCUS ELONGATUS MUTANTS, VARIANTS AND USES THEREOF TO PRODUCE AN ESSENTIAL AMINO ACID | July 2022 | July 2025 | Abandon | 36 | 4 | 1 | No | No |
| 17757368 | FERMENTATION METHOD AND USES THEREOF | June 2022 | August 2025 | Abandon | 38 | 0 | 1 | No | No |
| 17784162 | MICROBIAL COMPOSITIONS AND METHODS FOR TREATMENT AND DETECTION OF DISEASE | June 2022 | July 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17747379 | METHODS OF TREATING MYOINTIMAL PROLIFERATION | May 2022 | May 2025 | Abandon | 36 | 1 | 0 | No | No |
| 17663634 | BACTERIAL FORMULATION | May 2022 | April 2024 | Allow | 23 | 2 | 1 | Yes | No |
| 17738925 | FUNGAL COMPOUND COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATION | May 2022 | February 2024 | Abandon | 21 | 1 | 1 | No | No |
| 17736690 | METHODS FOR TREATING FARBER DISEASE | May 2022 | November 2025 | Abandon | 42 | 2 | 0 | No | No |
| 17736387 | LACTOBACILLUS ACIDOPHILUS TW01 ISOLATE AND USE THEREOF | May 2022 | April 2023 | Allow | 12 | 1 | 0 | No | No |
| 17772710 | Engineered Microorganism for the Production of Cannabinoids | April 2022 | January 2026 | Abandon | 45 | 1 | 1 | No | No |
| 17726970 | COMPOSITION FOR INHIBITING LIPOFUSCIN ACCUMULATION OR REMOVING LIPOFUSCIN | April 2022 | June 2023 | Allow | 14 | 2 | 0 | Yes | No |
| 17727462 | COMPOSITION FOR ELEVATING ABILITY OF BRAIN TISSUE AND USES THEREOF | April 2022 | September 2024 | Abandon | 29 | 4 | 1 | No | No |
| 17726041 | PROBIOTIC CULTURE AND USE THEREOF | April 2022 | April 2024 | Allow | 24 | 3 | 1 | Yes | No |
| 17724341 | METHOD FOR PROMOTING GROWTH OF PROBIOTIC MICROORGANISM | April 2022 | April 2024 | Allow | 24 | 2 | 0 | No | No |
| 17711401 | ENGINEERED GUANYLATE KINASE VARIANT ENZYMES | April 2022 | July 2025 | Allow | 40 | 4 | 1 | No | No |
| 17704346 | HEALTH-PROMOTING BEVERAGES | March 2022 | March 2024 | Abandon | 24 | 1 | 1 | No | No |
| 17701204 | METHODS FOR DEGRADING AHL SIGNALING MOLECULES OR PREVENTING PLANT DISEASE CAUSED THEREBY | March 2022 | October 2023 | Abandon | 19 | 1 | 1 | No | No |
| 17697564 | PD-L1 BINDING PROTEINS COMPRISING SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CD8+ T CELL ANTIGENS | March 2022 | April 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17675169 | METHOD OF IMPROVING DISEASES USING TRADITIONAL CHINESE MEDICINE POLYSACCHARIDES AND BACTERIAL COMPOSITION THEREOF | February 2022 | February 2024 | Abandon | 24 | 2 | 0 | No | No |
| 17669752 | LACTIC ACID BACTERIAL COMPOSITION FOR TREATING OR PREVENTING JAUNDICE | February 2022 | June 2023 | Allow | 16 | 1 | 1 | Yes | No |
| 17592510 | PROBIOTIC COMPOSITIONS AND USES THEREOF | February 2022 | April 2024 | Abandon | 26 | 3 | 1 | Yes | No |
| 17592575 | METHOD OF DISRUPTING MYCOTOXIN SYNTHESIS USING A COMPOSITION COMPRISING VIBRIO GAZOGENES | February 2022 | September 2023 | Abandon | 19 | 1 | 0 | No | No |
| 17631218 | TARGETING THE GASTROINTESTINAL BARRIER TO TREAT AGE-RELATED DISORDERS | January 2022 | June 2025 | Abandon | 41 | 1 | 1 | No | No |
| 17647983 | Sugarless peptide cultivated enzyme | January 2022 | November 2023 | Abandon | 22 | 2 | 0 | No | No |
| 17566598 | METHOD FOR PRODUCING HYDROGEN FROM PORK USING PHOTOSYNTHETIC ORGANISMS | December 2021 | August 2023 | Abandon | 20 | 1 | 0 | No | No |
| 17553517 | ANTIMICROBIAL COMPOSITION CONTAINING WASP EXTRACT AS ACTIVE INGREDIENT | December 2021 | July 2023 | Abandon | 19 | 1 | 0 | No | No |
| 17544733 | Methods of Identifying Bacteriophages that can Infect and Kill Host-Adapted Pathogenic Bacteria | December 2021 | October 2025 | Abandon | 47 | 2 | 1 | No | No |
| 17615914 | NUTRITIONAL COMPOSITIONS | December 2021 | March 2025 | Abandon | 40 | 2 | 0 | Yes | No |
| 17533536 | NOVEL COMPOSITIONS FOR TREATING COLITIS AND/OR PREVENTING COLON CANCER | November 2021 | January 2026 | Abandon | 49 | 4 | 1 | Yes | No |
| 17611316 | DIGESTION OF FORAGE CONTAINING LIGNOCELLULOSE WITH FIBROLYTIC ENZYMES AND RECOMBINANT BACTERIAL EXPANSINS | November 2021 | May 2025 | Abandon | 42 | 1 | 1 | No | No |
| 17520345 | Pyocyanine Demethylases and related Phenazine Degrading Agents Compositions, Methods and Systems for Interfering with Viability of Bacteria | November 2021 | May 2025 | Allow | 43 | 3 | 1 | Yes | No |
| 17507950 | AUTOMATIC DISHWASHING DETERGENT COMPOSITION | October 2021 | June 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17507167 | HOMOGENEOUS ENZYME IMMUNOASSAY FOR KERATINIZED STRUCTURES | October 2021 | May 2025 | Allow | 43 | 1 | 1 | No | No |
| 17603099 | MICROBES, COMPOSITIONS, AND USES FOR INCREASING PLANT YIELD AND/OR DROUGHT TOLERANCE | October 2021 | May 2025 | Allow | 43 | 2 | 1 | No | No |
| 17601316 | PRODUCTION METHOD TO INCREASE BIOAVAILABILITY OF SUGARS FROM NATURAL COMPLEX POLYSACCHARIDES FOR HUMAN, ANIMAL AND AGRICULTURAL PURPOSES | October 2021 | April 2024 | Allow | 31 | 4 | 0 | Yes | No |
| 17601244 | LYSINS AND DERIVATIVES THEREOF WITH BACTERICIDAL ACTIVITY AGAINST PSEUDOMONAS AERUGINOSA, IN THE PRESENCE OF HUMAN SERUM | October 2021 | February 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17598384 | METHOD OF TREATING BOVINE MASTITIS | September 2021 | December 2025 | Abandon | 51 | 5 | 1 | No | Yes |
| 17479381 | DUODENAL ADMINISTRATION OF BOTULINUM TOXIN | September 2021 | July 2023 | Abandon | 21 | 1 | 0 | No | No |
| 17279941 | AGENT FOR IMPROVING MITOCHONDRIAL FUNCTION | September 2021 | May 2024 | Allow | 37 | 3 | 1 | Yes | No |
| 17436356 | METHOD FOR PRODUCING SPIRULINA EXTRACT, AND SPIRULINA EXTRACT-CONTAINING PHARMACEUTICAL COMPOSITION AND HEALTH FUNCTIONAL FOOD FOR IMPROVING COGNITIVE ABILITY | September 2021 | March 2025 | Abandon | 42 | 1 | 1 | No | No |
| 17465931 | STREPTOCOCCUS BACTERIOPHAGE LYSINS FOR DETECTION AND TREATMENT OF GRAM POSITIVE BACTERIA | September 2021 | February 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17434080 | COMPOSITION COMPRISING LACTOBACILLUS SAKEI CVL-001 OR CULTURE LIQUID THEREOF FOR ALLEVIATING, PREVENTING, OR TREATING BONE DISEASES OR METABOLIC DISEASES | August 2021 | November 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17432812 | KIMCHI LACTOBACILLUS SAKEI HAVING PROPHYLACTIC, AMELIORATING OR THERAPEUTIC EFFECT ON DEPRESSION AND ANXIETY DISORDERS | August 2021 | September 2024 | Abandon | 37 | 1 | 0 | No | No |
| 17431144 | A LACTOBACILLUS PLANTARUM STRAIN AR113 WITH PROTECTION EFFECT ON APOPLEXY | August 2021 | June 2024 | Abandon | 34 | 2 | 0 | No | No |
| 17429905 | COMPOSITIONS CONTAINING BACILLAENE PRODUCING BACTERIA OR PREPARATIONS THEREOF | August 2021 | January 2025 | Abandon | 41 | 1 | 1 | Yes | No |
| 17423183 | COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING NEURODEGENERATIVE DISEASES, COMPRISING PEDIOCOCCUS INOPINATUS | July 2021 | July 2024 | Allow | 36 | 3 | 0 | No | No |
| 17345044 | COMPOSITIONS COMPRISING BACTERIAL STRAINS | June 2021 | April 2025 | Abandon | 46 | 2 | 0 | No | No |
| 17311155 | PROBIOTICS FOR COGNITIVE AND MENTAL HEALTH | June 2021 | December 2023 | Abandon | 31 | 1 | 0 | No | No |
| 17292993 | PROBIOTIC COMBINATION FOR TREATMENT OF ALLERGIC DISORDERS | May 2021 | October 2025 | Abandon | 53 | 4 | 0 | Yes | Yes |
| 17291325 | AGENT FOR CONTROLLING SEBACEOUS GLANDS | May 2021 | February 2024 | Abandon | 33 | 3 | 0 | Yes | No |
| 17309185 | METHODS AND COMPOSITIONS FOR TREATING INFECTIOUS, AUTOIMMUNE, AND ALLERGIC DISEASE | May 2021 | October 2025 | Allow | 54 | 4 | 1 | Yes | No |
| 17288616 | STABLE MICROBIAL COMPOSITION AND DRYING PROCESS | April 2021 | January 2026 | Allow | 57 | 2 | 1 | No | Yes |
| 17281673 | COMPOSITION COMPRISING TETRAGENOCOCCUS HALOPHILUS FOR PREVETION OR TREATMENT OF BEHCET'S DISEASE OR HERPES SIMPLEX VIRUS INFECTION | March 2021 | September 2024 | Abandon | 42 | 7 | 0 | No | No |
| 17215769 | BLUE FLUORESCENT PROTEIN MONOMERS AND USES THEREOF | March 2021 | September 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17200715 | HOST CELLS AND METHODS USEFUL FOR PRODUCING UNNATURAL TERPENOIDS USING A NOVEL ARTIFICIAL METALLOENZYME | March 2021 | July 2023 | Allow | 28 | 1 | 1 | Yes | No |
| 17273382 | METHODS FOR SUPPORTING WEIGHT LOSS AND WEIGHT LOSS MAINTENANCE BY ADMINISTRATION OF AQUATIC PLANTS AND/OR AUTOLOGOUS MICROBIOME SAMPLES | March 2021 | December 2023 | Abandon | 33 | 0 | 1 | No | No |
| 17272805 | METHOD FOR ENHANCING SENSITIVITY OF ENDOTOXIN MEASURING AGENT | March 2021 | December 2025 | Abandon | 57 | 4 | 1 | Yes | No |
| 17269660 | COMPOSITION COMPRISING ISOMERS OF INOSITOL AND ITS USE | February 2021 | January 2024 | Abandon | 35 | 1 | 0 | No | No |
| 17172503 | CELLULITE ERADICATION METHODS | February 2021 | November 2023 | Abandon | 34 | 1 | 0 | No | No |
| 17143045 | TWO PHASE SUSTAINABLE PHOTOPRODUCTION VIA CO-CULTIVATION OF ENCAPSULATED, CARBOHYDRATE-PRODUCING CYANOBACTERIA | January 2021 | January 2026 | Abandon | 60 | 4 | 1 | No | No |
| 17254495 | NOVEL OLIGOSACCHARIDES FOR USE IN PREBIOTIC APPLICATIONS | December 2020 | October 2023 | Abandon | 34 | 0 | 1 | No | No |
| 17252854 | LACTOBACILLUS PLANTARUM COMPOSITIONS AND USES THEREOF | December 2020 | October 2025 | Allow | 58 | 5 | 0 | Yes | No |
| 17058351 | DESIGNED BACTERIAL COMPOSITIONS AND USES THEREOF | November 2020 | March 2025 | Abandon | 52 | 2 | 1 | No | No |
| 17053324 | WELLBEING SUPPLEMENT FOR POSTPARTUM MATERNAL NUTRITION | November 2020 | March 2024 | Abandon | 40 | 1 | 1 | No | No |
| 17048278 | METHOD AND KIT FOR ASSISTING DIAGNOSIS OF DISEASE IN SUBJECT | October 2020 | June 2024 | Abandon | 44 | 0 | 1 | No | No |
| 17042991 | METHOD FOR PRODUCING COMPOSITION CONTAINING K-CASEIN GLYCOMACROPEPTIDE | September 2020 | November 2023 | Abandon | 37 | 2 | 0 | Yes | No |
| 17019677 | LACTOBACILLUS SP. STRAIN HAVING ABILITY TO INHIBIT GROWTH OF VAGINAL PATHOGENIC MICROORGANISMS | September 2020 | April 2024 | Allow | 43 | 2 | 0 | No | No |
| 16979161 | FUSION PROTEIN OF FLAVIN ADENINE DINUCLEOTIDE-GLUCOSE DEHYDROGENASE AND CYTOCHROME MOLECULE | September 2020 | August 2024 | Allow | 47 | 2 | 1 | Yes | No |
| 16975890 | NANOVESICLES DERIVED FROM BLAUTIA BACTERIA AND USE THEREOF | August 2020 | September 2024 | Abandon | 49 | 1 | 1 | No | No |
| 16962627 | ACTIVATION OF CONDITIONALLY-EXPRESSED OLIGOSACCHARIDE PATHWAYS DURING FERMENTATION OF PROBIOTIC STRAINS | July 2020 | November 2025 | Abandon | 60 | 3 | 1 | No | No |
| 16250850 | METHOD FOR QUANTIFYING THE AMOUNT OF CHOLESTEROL IN HIGH-DENSITY LIPOPROTEIN 3 | January 2019 | June 2025 | Allow | 60 | 3 | 1 | Yes | Yes |
| 16096549 | Systems, Devices and Methods for Sequential Analysis of Complex Matrix Samples for High Confidence Bacterial Detection and Drug Susceptibility Prediction Using a Flow Cytometer | October 2018 | December 2020 | Abandon | 26 | 5 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner DURYEE, ALEXANDER MARSH.
With a 66.7% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 50.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner DURYEE, ALEXANDER MARSH works in Art Unit 1657 and has examined 48 patent applications in our dataset. With an allowance rate of 27.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 42 months.
Examiner DURYEE, ALEXANDER MARSH's allowance rate of 27.1% places them in the 4% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by DURYEE, ALEXANDER MARSH receive 2.06 office actions before reaching final disposition. This places the examiner in the 54% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by DURYEE, ALEXANDER MARSH is 42 months. This places the examiner in the 18% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +34.4% benefit to allowance rate for applications examined by DURYEE, ALEXANDER MARSH. This interview benefit is in the 82% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 5.1% of applications are subsequently allowed. This success rate is in the 2% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 46.7% of cases where such amendments are filed. This entry rate is in the 71% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 40.0% of appeals filed. This is in the 7% percentile among all examiners. Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 61.5% are granted (fully or in part). This grant rate is in the 66% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.